Clinical Efficacy and Safety of Monthly Oral Ibandronate 100 Mg Versus Monthly Intravenous Ibandronate 1 Mg in Japanese Patients with Primary Osteoporosis

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2015 May 24

PMID 26001561

Citations 14

Authors

T Nakamura

M Ito

J Hashimoto

K Shinomiya

Y Asao

K Katsumata

H Hagino

T Inoue

T Nakano

H Mizunuma

Affiliations

Soon will be listed here.

Abstract

Unlabelled: The MOVEST study evaluated the efficacy and safety of monthly oral ibandronate versus licensed monthly IV ibandronate in Japanese osteoporotic patients. Relative BMD gains after 12 months were 5.22 % oral and 5.34 % IV, showing non-inferiority of oral to IV ibandronate (primary endpoint). No new safety concerns were identified.

Introduction: The randomized, phase 3, double-blind MOVEST (Monthly Oral VErsus intravenouS ibandronaTe) study evaluated the efficacy and safety of monthly oral ibandronate versus the licensed monthly intravenous (IV) ibandronate regimen in Japanese patients with osteoporosis.

Methods: Ambulatory patients aged ≥ 55 years with primary osteoporosis were randomized to receive oral ibandronate 100 mg/month plus monthly IV placebo, or IV ibandronate 1 mg/month plus monthly oral placebo. The primary endpoint was non-inferiority of oral versus IV ibandronate with respect to bone mineral density (BMD) gains at the lumbar spine after 12 months of treatment.

Results: Four hundred twenty-two patients were enrolled with 372 patients in the per-protocol set (183 and 189 in the oral and IV ibandronate groups, respectively). The relative change from baseline in lumbar spine BMD values for the oral and IV ibandronate groups, respectively, was 5.22 % (95 % confidence interval [CI] 4.65, 5.80) and 5.34 % (95 % CI 4.78, 5.90). The least squares mean difference between the two groups was -0.23 % (95 % CI -0.97, 0.51), showing non-inferiority of oral ibandronate to IV ibandronate (non-inferiority limit = -1.60). Changes in BMD values at other sites, and bone turnover marker levels in the oral ibandronate group, were comparable with those of the IV group. The safety profile was similar to that previously demonstrated; no new safety concerns were identified.

Conclusions: This study demonstrated the non-inferiority of oral ibandronate 100 mg/month to IV ibandronate 1 mg/month (licensed dose in Japan) in increasing lumbar spine BMD in Japanese patients with primary osteoporosis.

Citing Articles

Ibandronate Suppresses Changes in Apatite Orientation and Young's Modulus Caused by Estrogen Deficiency in Rat Vertebrae.

Ishimoto T, Saito M, Ozasa R, Matsumoto Y, Nakano T Calcif Tissue Int. 2022; 110(6):736-745.

PMID: 34989822 PMC: 9108105. DOI: 10.1007/s00223-021-00940-2.

Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis.

Uehara M, Nakamura Y, Suzuki T, Nakano M, Takahashi J J Clin Med. 2021; 10(22).

PMID: 34830702 PMC: 8624848. DOI: 10.3390/jcm10225420.

Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study.

Cho Y, Bae K, Lee D, Lee J Korean J Fam Med. 2020; 41(5):339-345.

PMID: 32447881 PMC: 7509122. DOI: 10.4082/kjfm.19.0110.

Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women.

Chiu W, Lin C, Yang W, Tsai K, Reginster J Osteoporos Int. 2019; 31(1):193-201.

PMID: 31642977 DOI: 10.1007/s00198-019-05127-y.

Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis.

Soen S, Kishimoto H, Hagino H, Sone T, Ohishi H, Fujimoto T J Bone Miner Metab. 2019; 38(1):86-98.

PMID: 31420748 DOI: 10.1007/s00774-019-01031-x.

References

Hagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T . Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen. Bone. 2013; 59:44-52. DOI: 10.1016/j.bone.2013.10.017. View

Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M . Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int. 2013; 93(2):137-46. PMC: 3717162. DOI: 10.1007/s00223-013-9734-6. View

Nakai K, Tobinai M, Hashimoto J, Iida S, Kawanishi T . The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties. Eur J Drug Metab Pharmacokinet. 2014; 41(2):139-47. PMC: 4819509. DOI: 10.1007/s13318-014-0242-5. View

Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T . A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int. 1999; 10(3):183-92. DOI: 10.1007/s001980050214. View

Mitchell D, Eusebio R, Pallone K, Kelly S, Nesbitt J, Brezovic C . Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol. 2000; 40(3):258-65. DOI: 10.1177/00912700022008928. View

Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M . Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab. 2001; 19(6):331-7. DOI: 10.1007/s007740170001. View

Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, MINAGUCHI H . A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int. 2002; 13(12):971-9. DOI: 10.1007/s001980200135. View

Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, MINAGUCHI H . A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int. 2003; 14(3):225-34. DOI: 10.1007/s00198-002-1369-9. View

Ogura Y, Gonsho A, Cyong J, Orimo H . Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. J Bone Miner Metab. 2004; 22(2):111-9. DOI: 10.1007/s00774-003-0458-y. View

10.

Chesnut 3rd C, Skag A, Christiansen C, Recker R, Stakkestad J, Hoiseth A . Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19(8):1241-9. DOI: 10.1359/JBMR.040325. View

11.

Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T . A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab. 2004; 22(5):469-78. DOI: 10.1007/s00774-004-0509-z. View

12.

Barrett J, Worth E, Bauss F, Epstein S . Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol. 2004; 44(9):951-65. DOI: 10.1177/0091270004267594. View

13.

Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M . Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab. 2005; 23(5):382-8. DOI: 10.1007/s00774-005-0616-5. View

14.

Cramer J, Amonkar M, Hebborn A, Altman R . Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005; 21(9):1453-60. DOI: 10.1185/030079905X61875. View

15.

Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V . Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 2005; 21(12):1895-903. DOI: 10.1185/030079905X74862. View

16.

Reginster J, Adami S, Lakatos P, Greenwald M, Stepan J, Silverman S . Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2005; 65(5):654-61. PMC: 1798147. DOI: 10.1136/ard.2005.044958. View

17.

Delmas P, Adami S, Strugala C, Stakkestad J, Reginster J, Felsenberg D . Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006; 54(6):1838-46. DOI: 10.1002/art.21918. View

18.

Cooper A, Drake J, Brankin E . Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006; 60(8):896-905. PMC: 1619408. DOI: 10.1111/j.1742-1241.2006.01059.x. View

19.

Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H . Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab. 2006; 24(5):405-13. DOI: 10.1007/s00774-006-0706-z. View

20.

Leslie W, Tsang J, Caetano P, Lix L . Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab. 2006; 92(1):77-81. DOI: 10.1210/jc.2006-1415. View